Proactive Investors
11 Jul 2026, 14:12 UTC · 2h ago
OKYO Pharma advances toward Phase 3 FDA trial - ICYMI
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Proactive Investors
11 Jul 2026, 14:12 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
The FDA provided positive feedback during a Type D meeting, potentially allowing OKYO Pharma to use a single-dose Phase 3 study as a single pivotal trial for urcosimod. — Reducing the number of required pivotal trials significantly lowers regulatory risk and shortens the timeline to potential commercialization.
+0.80OKYO Pharma intends to seek Breakthrough Therapy designation from the FDA for its neuropathic corneal pain treatment. — Breakthrough designation provides intensive FDA guidance and can lead to accelerated approval, though it is not guaranteed.
+0.50The company is finalizing 14 clinical sites across the US and Europe to enroll approximately 111 patients for the Neptune Phase 3 trial. — Concrete progress toward trial commencement demonstrates operational execution and moves the company closer to a data catalyst.
+0.30Continue reading
6 related stories
Search tags
There are currently no approved treatments for neuropathic corneal pain. — An unmet medical need implies a monopoly-like market opportunity if the drug receives approval.
+0.20Which stocks this story touches
The company received positive FDA feedback and is accelerating its drug candidate urcosimod toward a global Phase 3 pivotal study.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors
6h ago
